Lineage Cell Therapeutics And Christopher & Dana Reeve Foundation To Collaborate And Present 3Rd Annual Spinal Cord Injury Investor Symposium

Fully Virtual Event Scheduled for June 27, 2025

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations and the investment community, in order to discuss perspectives on current and future treatments, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and importantly, broaden awareness of and investment capital into SCI. The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025.